We reveal excessively activated pp38 MAPK-pMAPKAPK2 signaling expressed by EpCAM+ CD4+ T cells in tumor tissues in CC patients, indicating that the p38 MAPK pathway might be a potential therapeutic target in EpCAM+ CD4+ T cell-rich CC patients. This evidence concerns the gene CD4 and neoplasm.